Femring (Estradiol Acetate) Patent Expiration, LOE Window & CMS Spending
Femring (Estradiol Acetate) by Millicent Manufacturing Pr: Off-Patent Genericized (AB Competition), 31 AB generics, $8.0M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Millicent Manufacturing Pr |
| FDA Application & Pathway | N021367 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 31 |
| 2024 CMS Total Public Spend | $8.0M |
| 2024 Medicare Part D Spend | $7.0M |
| 2024 Medicaid Spend | $982K |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 31.1% 2-yr change) |